Bartl, T., Onoprienko, A., Hofstetter, G., Müllauer, L., Poetsch, N., Fuereder, T., . . . Grimm, C. (2021). Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients. MDPI AG.
Style de citation Chicago (17e éd.)Bartl, Thomas, Arina Onoprienko, Gerda Hofstetter, Leonhard Müllauer, Nina Poetsch, Thorsten Fuereder, Paul Kofler, Stephan Polterauer, et Christoph Grimm. Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients. MDPI AG, 2021.
Style de citation MLA (8e éd.)Bartl, Thomas, et al. Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients. MDPI AG, 2021.
Attention : ces citations peuvent ne pas être correctes à 100%.